Journal of Lipid Research
Volume 49, Issue 9, September 2008, Pages 1946-1954
Journal home page for Journal of Lipid Research

Research Article
A mechanism accounting for the low cellular level of linoleic acid in cystic fibrosis and its reversal by DHA*

https://doi.org/10.1194/jlr.M800035-JLR200Get rights and content
Under a Creative Commons license
open access

Specific fatty acid alterations have been described in the blood and tissues of cystic fibrosis (CF) patients. The principal alterations include decreased levels of linoleic acid (LA) and docosahexaenoic acid (DHA). We investigated the potential mechanisms of these alterations by studying the cellular uptake of LA and DHA, their distribution among lipid classes, and the metabolism of LA in a human bronchial epithelial cell model of CF. CF (antisense) cells demonstrated decreased levels of LA and DHA compared with wild type (WT, sense) cells expressing normal CFTR. Cellular uptake of LA and DHA was higher in CF cells compared with WT cells at 1 h and 4 h. Subsequent incorporation of LA and DHA into most lipid classes and individual phospholipids was also increased in CF cells. The metabolic conversion of LA to n-6 metabolites, including 18:3n-6 and arachidonic acid, was upregulated in CF cells, indicating increased flux through the n-6 pathway. Supplementing CF cells with DHA inhibited the production of LA metabolites and corrected the n-6 fatty acid defect. In conclusion, the evidence suggests that low LA level in cultured CF cells is due to its increased metabolism, and this increased LA metabolism is corrected by DHA supplementation.

arachidonic acid
docosahexaenoic acid
fatty acid alterations
lipid classes
n-6 pathway
phospholipids
supplementation
uptake

Cited by (0)

Published, JLR Papers in Press, May 14, 2008.

Abbreviations

AA, arachidonic acid

CE, cholesteryl ester

CF, cystic fibrosis

CFTR, cystic fibrosis transmembrane conductance regulator

DHA, docosahexaenoic acid

FAME, fatty acid methyl ester

LA, linoleic acid

PC, phosphatidylcholine

PE, phosphatidylethanolamine

PI, phosphatidylinositol

PL, phospholipid

PS, phosphatidylserine

TG, triglyceride

WT, wild type

*

This study was funded by National Institutes of Health Grant R01 DK-52765 (S.D.F.) and The Cystic Fibrosis Foundation (Grant FREEDM06A0) (S.D.F.).